80 Participants Needed

Multidisciplinary Clinic Evaluation for Sarcopenia Due to COPD

AA
Overseen ByAmy Attaway, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: The Cleveland Clinic
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores new methods to diagnose and treat sarcopenia, the loss of muscle mass, in individuals with COPD, a lung disease. The trial compares the outcomes of a specialized clinic with a team of experts (Implementation of a Sarcopenia Clinic) to the usual care patients receive. Researchers aim to determine if this new approach can help patients gain muscle and improve their health, thereby reducing hospital visits and flare-ups. The trial seeks participants who have been hospitalized for COPD, have lower muscle mass as seen on a CT scan, and have a history of heavy smoking. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could enhance future care for COPD patients.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that this multidisciplinary clinic approach is safe for diagnosing and treating sarcopenia in COPD patients?

Research shows that the multidisciplinary sarcopenia clinic aims to help people with COPD and muscle loss feel better. Some studies suggest that this type of clinic could help manage symptoms and improve quality of life. The clinic uses a team of specialists, such as lung doctors and nurses, to provide comprehensive care.

Regarding safety, previous research has not shown any clear evidence of harmful side effects from this clinic model. Since the trial is in an early phase, the treatment is likely considered safe enough for human testing. The studies reviewed have not reported any major adverse events (serious side effects).

So far, the approach seems well-tolerated, meaning most people can handle it without problems. However, discussing the risks and benefits with a healthcare provider before joining any trial is always important.12345

Why are researchers excited about this trial?

Researchers are excited about the implementation of a Sarcopenia Clinic for people with COPD because it offers a new, comprehensive approach to tackling muscle loss associated with the condition. Unlike traditional treatments that primarily focus on medication and pulmonary rehabilitation, this clinic combines expertise from various specialties to address sarcopenia from multiple angles. By integrating nutrition, exercise, and medical management, the Sarcopenia Clinic aims to not just slow muscle loss, but potentially improve muscle mass and strength more effectively than current standard care clinics.

What evidence suggests that this multidisciplinary clinic approach is effective for sarcopenia due to COPD?

Research shows that muscle loss, known as sarcopenia, is common and serious for people with COPD, a lung disease. Studies indicate that sarcopenia can worsen lung function and lead to more hospital visits. This trial will compare two approaches: a multidisciplinary sarcopenia clinic and a COPD standard of care clinic. A team-based approach, as used in the sarcopenia clinic, may improve muscle mass and overall health. Evidence suggests that these clinics, which include experts like doctors, nurses, and pharmacists, can improve outcomes for COPD patients. The goal is to increase muscle strength and reduce hospital visits. Early findings are promising, showing that sarcopenia is treatable, which could lead to better health for those with COPD.12678

Who Is on the Research Team?

AA

Amy Attaway, MD

Principal Investigator

The Cleveland Clinic

Are You a Good Fit for This Trial?

This trial is for COPD patients over 40 who've been hospitalized due to a COPD exacerbation, have low muscle mass shown by CT scans, and have moderate lung obstruction. They must have a history of significant smoking (at least 10 pack years).

Inclusion Criteria

I have smoked at least 10 pack-years.
I was hospitalized mainly due to a severe COPD flare-up or because of respiratory failure with a COPD flare-up.
My CT scans show I have low muscle mass in my chest area.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are enrolled in either the multidisciplinary sarcopenia clinic or the standard ambulatory COPD clinic for treatment and monitoring

1 year
Regular visits as per clinic schedule

Follow-up

Participants are monitored for safety and effectiveness after treatment, including skeletal muscle mass, mortality, hospitalizations, and COPD exacerbations

1 year

What Are the Treatments Tested in This Trial?

Interventions

  • Implementation of a Sarcopenia Clinic
Trial Overview The study tests if a specialized sarcopenia clinic can better diagnose and treat muscle loss in COPD patients compared to standard care. It involves evaluations by a team including pulmonologists and other specialists.
How Is the Trial Designed?
2Treatment groups
Active Control
Group I: COPD standard of care clinicActive Control1 Intervention
Group II: Sarcopenia clinicActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

The Cleveland Clinic

Lead Sponsor

Trials
1,072
Recruited
1,377,000+

Citations

Sarcopenia in chronic obstructive pulmonary diseaseThis study reviews the impact of sarcopenia in COPD and evaluates effective therapeutic strategies. Findings suggest that pulmonary ...
Clinical Research Trial Listing ( COPD | SarcopeniaThe goal of this study is to determine whether the multidisciplinary sarcopenia clinic improves outcomes compared to standard of care ambulatory ...
Sarcopenia as a Treatable Trait in COPDSarcopenia in COPD is a measurable, modifiable, and treatable trait linked to worse lung function, physical performance, and outcomes. Early ...
Prevalence and clinical characteristics of Sarcopenia in older ...The prevalence of sarcopenia in patients with COPD was reported to be 25% in Korea [12]. A relationship between sarcopenia and COPD has been ...
Sarcopenia in chronic obstructive pulmonary disease:...This study reviews the impact of sarcopenia in COPD and evaluates effective therapeutic strategies. Findings suggest that pulmonary rehabilitation, combined ...
Multidisciplinary Clinic Evaluation for Sarcopenia Due to ...This N/A medical study run by The Cleveland Clinic is evaluating whether Implementation of a Sarcopenia Clinic will have tolerable side effects & efficacy ...
Impact of COPD and sarcopenia on all-cause and respiratory ...Individuals with SAR are at increased risk of frailty, functional disability, falls, fractures, metabolic disorders, cognitive impairment, and ...
Sarcopenia Associated with Chronic Obstructive ...The prevalence of sarcopenia in stable COPD was reported to be 15% to 25% in previous foreign studies and 25% in a Korean study. As the amount of activity ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security